Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial.

ABSTRACT:

Objective

Recurrent pericarditis (RP) incurs significant morbidity. Rilonacept inhibits both interleukin-1 alpha (IL-1α) and IL-1β; these cytokines are thought to play a major role in RP. This phase II study evaluated rilonacept efficacy and safety in RP.

Methods

This multicentre, open-label study enrolled adult patients with idiopathic or postpericardiotomy RP, symptomatic (≥2 pericarditis recurrences) or corticosteroid (CS) dependent (≥2 recurrences prior).Patients received rilonacept 320 mg SC load/160 mg SC weekly maintenance in a 6-week base treatment period (TP) followed by an optional 18-week on-treatment extension period (EP) (option to wean background therapy).

Results

Outcomes: pericarditis pain (numeric rating scale (NRS)) and inflammation (C reactive prote

SUBMITTER: Klein AL 

PROVIDER: S-EPMC7925818 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature